Albuminuria, cardiovascular risk factors and disease management in subjects with type 2 diabetes: a cross sectional study
© Meisinger et al; licensee BioMed Central Ltd. 2008
Received: 13 March 2008
Accepted: 05 November 2008
Published: 05 November 2008
Epidemiological studies have shown that microalbuminuria is an important risk factor for arteriosclerosis, coronary heart disease and other vascular diseases in persons with type 2 diabetes. In the present study we examined the prevalence and risk factors for micro- and macroalbuminuria and examined glycemic control as well as treatment of modifiable cardiovascular risk factors in persons with known type 2 diabetes in Germany.
The presented data were derived from the 'KORA Augsburg Diabetes Family Study', conducted between October 2001 and September 2002. Participants were adults aged 29 years and older with previously diagnosed type 2 diabetes (n = 581). Microalbuminuria was defined as an albumin-creatinine ratio of 30 to 300 mg/g, and macroalbuminuria as an albumin-creatinine ratio of more than 300 mg/g.
Microalbuminuria was revealed in 27.2% and macroalbuminuria in 9.0% of the 581 included diabetic persons. Multivariable regression analysis identified HBA1c, duration of diabetes, systolic blood pressure, serum creatinine, smoking and waist circumference as independent risk factors associated with albuminuria (micro- or macroalbuminuria). Relatively few persons with type 2 diabetes achieved treatment targets of HbA1c < 7% (46.6%), total cholesterol < 200 mg/dl (44.1%), and LDL cholesterol < 100 mg/dl (16.0%). Optimal HDL cholesterol values (> 45 mg/dl in men, > 55 mg/dl in women) were found in 55.8%, and blood pressure values < 130 and < 85 mmHg in 31.3% of the persons
Albuminuria is common among German persons with known type 2 diabetes. Despite evidence-based guidelines, only a small proportion of type 2 diabetic persons achieved the recommended levels of glycemic control and control of cardiovascular risk factors.
Throughout the world, the number of people developing type 2 diabetes mellitus is increasing dramatically. At the present time the disease affecting around 171 million people worldwide and the World Health Organization predicts that this number will rise to 366 million by 2030 . Consequently, the number of people developing diabetes-related complications will increase. Microalbuminuria is a common complication of diabetes and appears to be a strong predictor of subsequent development of overt diabetic nephropathy , which is the leading cause of end-stage renal disease in the western world [3, 4]. Without any intervention, among type 2 diabetic patients about 20–40% with microalbuminuria progress to overt nephropathy and finally approximately 20% develop end stage renal failure [5, 6]. However, microalbuminuria does not only predict future risk of renal injury but is also considered to be associated with an increased risk of cardiovascular events and mortality .
Prior studies have shown that the risk factors correlated with the progression of nephropathy in persons with type 2 diabetes are blood pressure, lipid levels, obesity, cigarette smoking, glycaemic control, and anemia [8, 9]. Thus, studies on diabetes related complications are very important to estimate the consequence and burden of diabetes. The aims of the present study are to determine the prevalence of and factors associated with micro- and macroalbuminuria in persons with type 2 diabetes and to examine the achievement of international guideline targets with regard to glycaemic control and the management of modifiable cardiovascular risk factors.
The presented data were derived from the 'Augsburg Diabetes Family Study' which was conducted between October 2001 and September 2002. The primary goal of the study was to enrol families to investigate the role of genes as well as environmental factors in the development of type 2 diabetes . Families were ascertained through an index proband with known type 2 diabetes having at least one full sib or both parents willing to participate in the study. All index probands came from the study region of Augsburg. Altogether 1532 subjects (755 men, 777 women; 614 index probands, 918 full sibs and parents) aged 20 to 98 years could be examined in the KORA (Cooperative health research in the region of Augsburg) study centre. For the present study only index probands with known type 2 diabetes were included (n = 614). We excluded from the present analysis 33 subjects with missing values on any of the considered risk factors. Finally, the analyses comprised 581 type 2 diabetic subjects (352 men and 229 women) aged 29 to 83 years.
The study was conducted according to the principles expressed in the Declaration of Helsinki as revised in 2000 and was approved by the ethics committee of the Bavarian Medical Association. All participants gave their written informed consent.
Baseline information on sociodemographic variables, smoking habits, physical activity level, medication use, parental history of diseases, and alcohol consumption were gathered by trained medical staff (mainly nurses) during a standardized face to face interview. Individuals with known type 2 diabetes were asked to report their age at disease onset. Anthropometric measurements were made by trained personnel, subjects wearing light indoor clothing and no shoes. Body weight was measured to the nearest 0.1 kg, height to the nearest mm, and waist and hip circumferences to the nearest mm while the proband was standing. Blood pressure was measured at the right arm in a sitting position after a fifteen-minute rest using a validated automatic device (OMRON 705-CP); 3 measurements were taken with 3-minute intervals between the measurements. For the present analysis, the results of the second and third measurements were averaged
Total cholesterol was determined by cholesterol-esterase method (CHOL Flex, Dade-Behring, Germany), HDL cholesterol using the AHDL Flex (Dade-Behring), and LDL cholesterol was measured by a direct homogeneous method (GreinerBiochemica, Germany), respectively. Urinary albumin and creatinine levels were determined in a random spot urine specimen (Tina-Quant, Roche Diagnostics for the measurement of urinary albumin and KREA Flex, Dade-Behring, for the measurement of urinary creatinine). Serum creatinine was determined using a modified Jaffe test (KREA Flex, Dade-Behring), and serum uric acid was measured using an enzymatic colorimetric test (URCA Flex, Dade-Behring). HbA1c was determined by a turbidimetric immunological inhibition assay (TINIA, Dade-Behring).
Definition of variables
Body mass index (BMI) was calculated as weight in kilograms divided by height in square meters and waist-to-hip ratio as waist divided by hip circumference. Dyslipidemia was defined as total cholesterol to HDL cholesterol ratio ≥ 5. Education level was categorized into 'low' (< 12 years of schooling) and 'high' (≥ 12 years of schooling). A regular smoker was defined as a subject who smoked at least one cigarette per day. Alcohol intake was classified into the three categories 0, 0.1–19.9, and 20.0 or more g/day for women and 0, 0.1–39.9, and 40 or more g/day for men. Participants were defined as active during leisure time if they regularly participated in sports in summer and winter and if they were active for at least 1 hour per week in either season. The abbreviated Modification of Diet in Renal Disease (MDRD) Study Group equation was used to calculate eGFR: eGFR (mL/min/1.73 m2) = 186.3 × (serum creatinine-1.154) × (age-0.203) × 0.742 (if female) × 1.212 (if black) . Microalbuminuria was defined as an albumin-creatinine ratio of 30 to 300 mg/g, and macroalbuminuria as an albumin-creatinine ratio of more than 300 mg/g.
Self-reported type 2 diabetes was validated by hospital records or by contacting the proband's treating physician.
To be comparable with previous studies, due to the guidelines from the European Society of Hypertension-European Society of Cardiology , the American Diabetes Association , and the Joint National Committee VII , the following recommended targets were considered in the present paper: < 7.0% for HbA1c, < 130/85 mmHg for blood pressure, < 100 mg/dl for LDL cholesterol, < 200 mg/dl for total cholesterol, < 25 kg/m2 for BMI, and > 45 mg/dl (men) and > 55 mg/dl (women) for HDL cholesterol.
Means or proportions for baseline clinical and laboratory characteristics were computed for subjects with and without micro- or macroalbuminuria. The Chi2-Test was used to test the differences in prevalences. The general linear model was used to compare means (F-Test). Multiple logistic regression analysis was done using albuminuria (including micro- and macroalbuminuria) as the dependent variable and age, sex, BMI, waist circumference, diastolic blood pressure, systolic blood pressure, total cholesterol values, HbA1c values, duration of diabetes, serum creatinine, and regular smoking as independent variables. Significance tests were two tailed and p-values less than 0.05 are stated as statistically significant. All analyses were performed using the Statistical Analysis System (Version 9.1, SAS Institute Inc., Cary, NC).
Microalbuminuria was revealed in 158 of 581 diabetic persons (27.2%) and proteinuria was found in 52 of 581 diabetic persons (9.0%).
Characteristics of the study participants
Clinical characteristics and laboratory parameters in all study participants and diabetic participants with normoalbuminuria, microalbuminuria, and macroalbuminuria
All study participants
N = 581
n = 371
n = 158
n = 52
Duration of diabetes (years)
Waist circumference (cm)
Systolic blood pressure (mmHg)
Diastolic blood pressure (mmHg)
Regular smoker (%)
Physical inactivity (%)
Alcohol intake 0 g/day (%)
0.1–39.9 (men) 0.1–19.9 (women) (%)
≥ 40 g/day (men) ≥ 20 g/day (women) (%)
History of cardiovascular events (%)
Serum creatinine (mg/dl)*
GFR (ml/min per 1.73 m2)**
Total cholesterol (mg/dl)
LDL cholesterol (mg/dl)
HDL cholesterol (mg/dl)
Serum uric acid (mg/dl)
Risk factors associated with albuminuria
Multiple logistic regression analysis using albuminuria as a dependent variable
OR (95% CI)
1.25 (1.09 – 1.44)
Duration of diabetes (years)
1.05 (1.02 – 1.07)
Systolic blood pressure (mmHg)
1.03 (1.02 – 1.04)
Serum creatinine (mg/dl)*
4.27 (2.09 – 8.70)
2.07 (1.20 – 3.57)
Waist circumference (cm)
1.02 (1.01 – 1.04)
Antidiabetic and cardiovascular drug treatment
Antidiabetic medication in diabetic participants with normoalbuminuria, microalbuminuria, and macroalbuminuria
n = 371
n = 158
n = 52
Oral antidiabetic medication only (%)
Insulin only (%)
Oral antidiabetic medication in combination with insulin (%)
No antidiabetic drug
Beta blockers (%)
ACE inhibitors (%)
Diuretic use (%)
AT 1 blockers (%)
Calcium channels blockers (%)
Lipid lowering drugs (%)
Antiplatelet drugs (%)
In comparison with normoalbuminuric participants, subjects with micro- and macroalbuminuria were significantly more frequently treated with diuretics (37.5%, 50.0% and 51.9%, respectively) and beta-blockers (40.2%, 38.6%, and 57.7%, respectively). For ACE inhibitors, AT1 blockers, calcium channel blockers as well as lipid lowering drugs and antiplatelets there were no statistically significant differences between the three groups (Table 3).
Glycemic control and treatment of cardiovascular risk factors
The percentage of type 2 diabetic participants who achieved optimal treatment goals for modifiable risk factors
HbA1c < 7%
Total cholesterol < 200 mg/dl
HDL cholesterol > 45 mg/dl (men), > 55 mg/dl (women)
LDL cholesterol < 100 mg/dl
Blood pressure < 130 and 85 mmHg
BMI < 25 kg/m2
The present study conducted in a study sample of type 2 diabetic persons recruited from the general population with median diabetes duration of 7.0 years showed that microalbuminuria (27.2%) and macroalbuminuria (9.0%) is common among German persons with known type 2 diabetes. Logistic regression modeling identified HBA1c, duration of diabetes, systolic blood pressure, serum creatinine, smoking and waist circumference as independent risk factors associated with albuminuria. In this study neither adequate glycemic control nor optimal treatment of modifiable cardiovascular risk factors according to guidelines was achieved in persons with type 2 diabetes.
Because the results of hitherto existing studies on this issue are based on different population characteristics (ethnicity, duration of diabetes, age-range, inclusion of type 1 and type 2 diabetic persons) direct comparisons with regard to the prevalence of microalbuminuria and macroalbuminuria between the investigations are difficult. So far, only a few studies of albuminuria in patients with type 2 diabetes anywhere in the world were population-based [15–18]. In the Third National Health and Nutrition Examination Survey, the prevalence of albuminuria was 34% (28.1% microalbuminuria, 6.1% macroalbuminuria) among persons with previously diagnosed type1 and type 2 diabetes , whereas in a study from Italy  the prevalence of albuminuria was 49.7% in known type 2 diabetic persons (32.1% microalbuminuria, 17.6% macroalbuminuria). In a prior German study including patients with recently diagnosed type 2 diabetes 19% exhibited microalbuminuria and 5.2% macroalbuminuria . Furthermore, another study including diabetic patients treated in primary care reported a prevalence of microalbuminuria (macroalbuminuria) of 17.2% (10.8%) in Type 2 diabetes . Although the present study was not population-representative the proportion of microalbuminuria and macroalbuminuria is similar to that reported in other studies and gives therefore a realistic estimation of the prevalence of albuminuria among type 2 diabetic persons in Germany [16–20].
In the present study HbA1c level, duration of diabetes, systolic blood pressure, serum creatinine, regular smoking, and waist circumference were significantly associated with albuminuria. This finding is in agreement with other studies, which also reported that diabetes duration [18, 21], and hypertension [18, 21] are important factors in the development of albuminuria. So far, only a few studies have found that smoking is a risk factor for albuminuria among persons with type 2 diabetes . In this study, persons who smoked regularly were twice as likely to have albuminuria compared with those who did not. Furthermore, in agreement with other studies, in our study HbA1c levels were also associated with the development of albuminuria . While other studies mostly identified BMI as risk factor for albuminuria , in our study waist circumference was more strongly associated with albuminuria than BMI.
In the present study persons with micro- or macroalbuminuria were more frequently treated with insulin alone or with insulin in combination with oral antidiabetic drugs in comparison to normoalbuminuric type 2 diabetes mellitus persons. This result is plausible and in agreement with findings from other studies , because intensification of treatment reflects the natural progression of the disease; due to long-standing disease complications and comorbidities occur which require insulin therapy to manage type 2 diabetes persons.
Results from randomized clinical trials demonstrated that control of glucose levels as well as blood pressure, and cholesterol levels can delay or prevent the macrovascular and microvascular complications of diabetes [25–28]. Despite the guidelines, developed on the basis of such data, in the present study only a small proportion of persons with type 2 diabetes achieved the recommended levels of control. This is in accordance with results from other studies [24, 29–31].
The Augsburg Diabetes Family Study has several limitations that need to be considered. The present study was cross-sectional in design, thus, longitudinal trends in the management of diabetes and modifiable risk factors could not be taken into account. Furthermore, a single random spot urine sample was used to determine albuminuria. Unfortunately, in the present study no data on the reproducibility of the urinary albumin excretion measurement was available. Although the study participants were recruited from the general population the present study was not population representative in design. Furthermore, selection bias cannot be excluded, as the study population could be expected to include an above average proportion of motivated persons with type 2 diabetes. This selection may have underestimated the reported prevalences of albuminuria and shortcomings in disease management.
However, the present study has also a number of strengths. Contrary to some prior studies, which were conducted in selected, e.g. clinic-based, patient groups [21, 31] the present study was based on study participants recruited from the general population. Also, studies on this issue based on a well characterized study population as the present one including a great number of phenotypes, risk factors and comorbidities are scarce. Furthermore, contrary to other papers on this subject [17, 18] the present paper additionally contains data on antidiabetic and cardiovascular treatment. In addition, this study is one of relatively few from Germany dealing with microalbuminuria. Thus, since type 2 diabetes is one of the most common health problems in primary care, we believe that our results can be applied to improve the management of cardiovascular risk factors, glycemic control and microalbuminuria in patients with type 2 diabetes.
In conclusion, the present study could show that the prevalences of microalbuminuria and macroalbuminuria in a German sample of persons with type 2 diabetes were comparable to those shown in other studies. Despite the high risk of cardiovascular events and mortality among type 2 diabetic persons, in our study control of diabetes and risk factors was not optimal. Thus, glycemic control and management of cardiovascular risk factors should be intensified to effectively reduce the risk of micro- and macrovascular complications in diabetic persons.
The KORA research platform and the MONICA/KORA Augsburg studies are financed by the Helmholtz Zentrum München, German Research Center for Environmental Health (GmbH), which is funded by the German Federal Ministry of Education, Science, Research and Technology and by the State of Bavaria. The Augsburg Diabetes Family Study was in addition supported by grants from the German Research Foundation (DFG-FKZ: WI 621/8-1). This research was supported by Lilly Germany GmbH, Bad Homburg. We thank all members of the Helmholtz Zentrum München, Institute of Epidemiology and the field staff in Augsburg who were involved in the conduct of the studies.
- The World Health Organization. The Diabetes Program 2004. [http://www.who.int/diabetes/en]
- Deckert T, Kofoed-Enevoldsen A, Norgaard K, Borch-Johnsen K, Feldt-Rasmussen B, Jensen T: Microalbuminuria: implications for micro- and macro-vascular disease. Diabetes Care. 1992, 15: 1181-1191. 10.2337/diacare.15.9.1181.View ArticlePubMedGoogle Scholar
- Ritz E: Nephropathy in type 2 diabetes. J Intern Med. 1999, 245: 111-126. 10.1046/j.1365-2796.1999.00411.x.View ArticlePubMedGoogle Scholar
- Raine AE: Epidemiology, development and treatment of end-stage renal failure in type 2 (non-insulin-dependent) diabetic patients in Europe. Diabetologia. 1993, 36: 1099-1104. 10.1007/BF02374505.View ArticlePubMedGoogle Scholar
- Parving HH, Gall MA, Skott P, Jorgensen HE, Lokkegaard H, Jorgensen F, Nielsen B, Larsen S: Prevalence and causes of albuminuria in non-insulin-dependent diabetic patients. Kidney Int. 1992, 41: 758-762. 10.1038/ki.1992.118.View ArticlePubMedGoogle Scholar
- Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR: Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003, 63 (1): 225-232. 10.1046/j.1523-1755.2003.00712.x.View ArticlePubMedGoogle Scholar
- Rossing P: Predictors of mortality in insulin-dependent diabetes: 10-year observational follow-up study. BMJ. 1996, 313: 779-784.View ArticlePubMedPubMed CentralGoogle Scholar
- Rossing K, Christensen PK, Hovind P, Tarnow L, Rossing P, Parving HH: Progression of nephropathy in type 2 diabetic patients. Kidney Int. 2004, 66: 1596-1605. 10.1111/j.1523-1755.2004.00925.x.View ArticlePubMedGoogle Scholar
- Mohanram A, Zhang Z, Shahinfar S, Keane WF, Brenner BM, Toto RD: Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy. Kidney Int. 2004, 66: 1131-1138. 10.1111/j.1523-1755.2004.00863.x.View ArticlePubMedGoogle Scholar
- Kuch B, von Scheidt W, Peter W, Döring A, Piehlmeier W, Landgraf R, Meisinger C: Sex-specific determinants of left ventricular mass in pre-diabetic and type 2 diabetic subjects: the Augsburg Diabetes Family Study. Diabetes Care. 2007, 30: 946-952. 10.2337/dc06-2123.View ArticlePubMedGoogle Scholar
- Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G: National kidney foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003, 139: 137-147.View ArticlePubMedGoogle Scholar
- European Society of Hypertension-European Society of Cardiology Guidelines Committee: Guidelines for the management of arterial hypertension. J Hypertens. 2003, 21: 1011-1053. 10.1097/00004872-200306000-00001.View ArticleGoogle Scholar
- American Diabetes Association: Standards of medical care in diabetes. Diabetes Care. 2005, 28: S4-S36. 10.2337/diacare.28.suppl_1.S4.View ArticleGoogle Scholar
- Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jones DW, Materson BJ, Oparil S, Wright JT, Roccella EJ: Seventh report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. Hypertension. 2003, 42: 1206-1252. 10.1161/01.HYP.0000107251.49515.c2.View ArticlePubMedGoogle Scholar
- Herman WH, Aubert RE, Engelgau MM, Thompson TJ, Ali MA, Sous ES, Hegazy M, Badran A, Kenny SJ, Gunter EW, Malarcher AM, Brechner RJ, Wetterhall SF, DeStefano F, Smith PJ, Habib M, abd el Shakour S, Ibrahim AS, el Behairy EM: Diabetes mellitus in Egypt: Glycaemic control of microvascular and neuropathic complications. Diabet Med. 1998, 15: 1045-1051. 10.1002/(SICI)1096-9136(1998120)15:12<1045::AID-DIA696>3.0.CO;2-L.View ArticlePubMedGoogle Scholar
- Bruno G, Cavallo-Perin P, Bargero G, Borra M, Calvi V, D'Errico N, Deambrogio P, Pagano G: Prevalence and risk factors for micro- and macroalbuminuria in an Italian population-based cohort of NIDDM subjects. Diabetes Care. 1996, 19: 43-47. 10.2337/diacare.19.1.43.View ArticlePubMedGoogle Scholar
- Garg AX, Kiberd BA, Clark WF, Haynes RB, Clase CM: Albuminuria and renal insufficiency prevalence guides population screening: Results from the NHANES III. Kidney Int. 2002, 61: 2165-2175. 10.1046/j.1523-1755.2002.00356.x.View ArticlePubMedGoogle Scholar
- Tapp RJ, Shaw JE, Zimmet PZ, Balkau B, Chadban SJ, Tonkin AM, Welborn TA, Atkins RC: Albuminuria is evident in the early stages of diabetes onset: results from the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Am J Kidney Dis. 2004, 44: 792-798. 10.1016/S0272-6386(04)01079-0.View ArticlePubMedGoogle Scholar
- Standl E, Stiegler H: Microalbuminuria in a random cohort of recently diagnosed type 2 (non-insulin-dependent) diabetic patients living in the greater Munich area. Diabetologia. 1993, 36 (10): 1017-1020. 10.1007/BF02374493.View ArticlePubMedGoogle Scholar
- Piehlmeier W, Renner R, Schramm W, Kimmerling T, Garbe S, Proetzsch R, Fahn J, Piwernetz K, Landgraf R: Screening of diabetic patients for microalbuminuria in primary care – The PROSIT-Project. Proteinuria Screening and intervention. Exp Clin Endocrinol Diabetes. 1999, 107 (4): 244-251.View ArticlePubMedGoogle Scholar
- Varghese A, Deepa R, Rema M, Mohan V: Prevalence of microalbuminuria in type 2 diabetes mellitus at a diabetes centre in southern India. Postgrad Med J. 2001, 77: 399-402. 10.1136/pmj.77.908.399.View ArticlePubMedPubMed CentralGoogle Scholar
- Gambaro G, Bax G, Fusaro M, Normanno M, Manani SM, Zanella M, Dangelo A, Fedele D, Favaro S: Cigarette smoking is a risk factor for nephropathy and its progression in type 2 diabetes mellitus. Diabetes Nutr Metab. 2001, 14: 337-342.PubMedGoogle Scholar
- Chan JC, Cheung CK, Swaminathan R, Nicholls MG, Cockram CS: Obesity, albuminuria and hypertension among Hong Kong Chinese with non-insulin-dependent diabetes mellitus (NIDDM). Postgrad Med J. 1993, 69: 204-210.View ArticlePubMedPubMed CentralGoogle Scholar
- Liebl A, Mata M, Eschwège E: Evaluation of risk factors for development of complications in Type II diabetes in Europe. Diabetologia. 2002, 45: S23-S28. 10.1007/s00125-002-0874-x.View ArticlePubMedGoogle Scholar
- UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in Type 2 diabetes : UKPDS 38. BMJ. 1998, 317: 703-713.View ArticlePubMed CentralGoogle Scholar
- Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S: Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998, 351: 1755-1762. 10.1016/S0140-6736(98)04311-6.View ArticlePubMedGoogle Scholar
- Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G: Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care. 1997, 20: 614-620. 10.2337/diacare.20.4.614.View ArticlePubMedGoogle Scholar
- Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003, 348 (5): 383-393. 10.1056/NEJMoa021778.View ArticlePubMedGoogle Scholar
- Saydah SH, Fradkin J, Cowie CC: Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA. 2004, 291: 335-342. 10.1001/jama.291.3.335.View ArticlePubMedGoogle Scholar
- Charpentier G, Genès N, Vaur L, Amar J, Clerson P, Cambou JP, Gueret P, ESPOIR Diabetes Study Investigators: Control of diabetes and cardiovascular risk factors in patients with type 2 diabetes: a nationwide French survey. Diabetes Metab. 2003, 29: 152-158. 10.1016/S1262-3636(07)70022-8.View ArticlePubMedGoogle Scholar
- Beaton SJ, Nag SS, Gunter MJ, Gleeson JM, Sajjan SS, Alexander CM: Adequacy of glycemic, lipid, and blood pressure management for patients with diabetes in a managed care setting. Diabetes Care. 2004, 27: 694-698. 10.2337/diacare.27.3.694.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1472-6963/8/226/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.